As previously reported, Guggenheim analyst David Westenberg initiated coverage of Illumina with a Buy rating and $350 price target, calling the stock the "best way to invest in genomic medicine." He thinks bear arguments around instrument cycles or PopSEQ funding delays have created an attractive entry point into the stock and recommends investors focus on emerging clinical sequencing opportunities where growth appears to be accelerating. Illumina has limited competitors in its fastest growing business areas and he sees it remaining one of the key technologies in the genomic medicine of the next decade, Westenburg added.